Literature DB >> 1323712

Partial elimination of Epstein-Barr virus plasmids from Burkitt's lymphoma cells by transfecting the BZLF1 gene.

K Takada1, Z Ji, S Fujiwara, N Shimizu, A Tanabe-Tochikura.   

Abstract

Epstein-Barr virus (EBV) nonproducer Raji cells stably maintain approximately 45 copies of the EBV genome per cell, depending on the presence of the EBV-determined nuclear antigen 1 (EBNA-1) protein. We found that transfection of the EBV BZLF1 gene causes the disappearance of EBNA proteins on Western blots (immunoblots). On the basis of these results, we attempted to eliminate EBV plasmids in Raji cells by transfecting a BZLF1 plasmid. Among 33 clones that were cotransfected with a BZLF1 plasmid and a hygromycin B resistance plasmid and selected resistant for hygromycin B, 24 clones had decreased numbers of EBV plasmids, as revealed by the decrease in the intensity of the EBV band on Southern blots compared with that of nontransfected Raji cells.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1323712      PMCID： PMC289120     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  27 in total

1.  Identification of sequences in Epstein-Barr virus DNA required for the expression of the second Epstein-Barr virus-determined nuclear antigen in COS-1 cells.

Authors:  A Ricksten; C Svensson; C Welinder; L Rymo
Journal:  J Gen Virol       Date:  1987-09       Impact factor: 3.891

2.  An Epstein-Barr virus-producer line Akata: establishment of the cell line and analysis of viral DNA.

Authors:  K Takada; K Horinouchi; Y Ono; T Aya; T Osato; M Takahashi; S Hayasaka
Journal:  Virus Genes       Date:  1991-04       Impact factor: 2.332

3.  A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection.

Authors:  B Sugden; N Warren
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

4.  Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease.

Authors:  L Young; C Alfieri; K Hennessy; H Evans; C O'Hara; K C Anderson; J Ritz; R S Shapiro; A Rickinson; E Kieff
Journal:  N Engl J Med       Date:  1989-10-19       Impact factor: 91.245

5.  The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters.

Authors:  S Kenney; J Kamine; E Holley-Guthrie; J C Lin; E C Mar; J Pagano
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

6.  Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity.

Authors:  D Wang; D Liebowitz; F Wang; C Gregory; A Rickinson; R Larson; T Springer; E Kieff
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

7.  Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA.

Authors:  J Countryman; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

8.  Constitutive expression of Epstein-Barr virus-encoded RNAs and nuclear antigen during latency and after induction of Epstein-Barr virus replication.

Authors:  R Weigel; D K Fischer; L Heston; G Miller
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

9.  A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components.

Authors:  D Reisman; J Yates; B Sugden
Journal:  Mol Cell Biol       Date:  1985-08       Impact factor: 4.272

10.  Synchronous and sequential activation of latently infected Epstein-Barr virus genomes.

Authors:  K Takada; Y Ono
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103
View more
  5 in total

1.  The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to loss of BamHI-Q promoter activity.

Authors:  H Chen; J M Lee; Y Wang; D P Huang; R F Ambinder; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

2.  Analysis of the BZLF1 promoter of Epstein-Barr virus: identification of an anti-immunoglobulin response sequence.

Authors:  N Shimizu; K Takada
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

3.  Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV.

Authors:  N Shimizu; A Tanabe-Tochikura; Y Kuroiwa; K Takada
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

4.  Epithelial cell retention of transcriptionally active, P3HR-1-derived heterogeneous Epstein-Barr virus DNA with concurrent loss of parental virus.

Authors:  Kazufumi Ikuta; Mingyu Ding; Fangfang Zhang; John W Sixbey; Rona S Scott
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

5.  A defective, rearranged Epstein-Barr virus genome in EBER-negative and EBER-positive Hodgkin's disease.

Authors:  Yan-Jun Gan; Bassem I Razzouk; Tao Su; John W Sixbey
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.